Frank Hoentjen

6.1k total citations
165 papers, 2.7k citations indexed

About

Frank Hoentjen is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Frank Hoentjen has authored 165 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Genetics, 84 papers in Epidemiology and 37 papers in Immunology. Recurrent topics in Frank Hoentjen's work include Inflammatory Bowel Disease (107 papers), Microscopic Colitis (73 papers) and Autoimmune and Inflammatory Disorders (15 papers). Frank Hoentjen is often cited by papers focused on Inflammatory Bowel Disease (107 papers), Microscopic Colitis (73 papers) and Autoimmune and Inflammatory Disorders (15 papers). Frank Hoentjen collaborates with scholars based in Netherlands, Canada and United States. Frank Hoentjen's co-authors include Lauranne Derikx, Bas Oldenburg, Levinus A. Dieleman, Nanne K.H. de Boer, Joost P.H. Drenth, Lisa Smits, Dirk J. de Jong, Ad A. van Bodegraven, Michiel E. de Jong and David T. Rubin and has published in prestigious journals such as Blood, Gastroenterology and PLoS ONE.

In The Last Decade

Frank Hoentjen

153 papers receiving 2.7k citations

Peers

Countries citing papers authored by Frank Hoentjen

Since Specialization

Citations

This map shows the geographic impact of Frank Hoentjen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Hoentjen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Hoentjen more than expected).

Fields of papers citing papers by Frank Hoentjen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Hoentjen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Hoentjen. The network helps show where Frank Hoentjen may publish in the future.

Co-authorship network of co-authors of Frank Hoentjen

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Hoentjen. A scholar is included among the top collaborators of Frank Hoentjen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Hoentjen. Frank Hoentjen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DOP049 Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial 2025 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Filip Baert, Peter Bossuyt, Mark Löwenberg, (unknown), Frank Hoentjen, Tamás Molnár, Geert D’Haens, Séverine Vermeire	0
2	Network analysis of extraintestinal manifestations and associated autoimmune disorders in Crohn’s disease and ulcerative colitis 2025 ·npj Digital Medicine ·Daniel C. Baumgart, (unknown), (unknown), Michael Parkes, Daniel Sadowski, Eytan Wine, Frank Hoentjen, Brendan P. Halloran, Aldo J. Montaño‐Loza, Sergio Zepeda-Gómez, Karen Wong, Farhad Peerani, (unknown), (unknown)	2
3	Relating the molecular phenotype of ulcerative colitis to the clinical course 2025 ·Scientific Reports ·Katelynn S. Madill-Thomsen, Jeffery M. Venner, (unknown), Konrad S. Famulski, Aducio Thiesen, (unknown), Karen I. Kroeker, Karen Wong, Farhad Peerani, Levinus A. Dieleman, Frank Hoentjen, Daniel C. Baumgart, Philip F. Halloran, Brendan P. Halloran	1
4	Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study 2025 ·The American Journal of Gastroenterology ·Virginia Solitano, Ropo Ebenezer Ogunsakin, Yuhong Yuan, Çharles N. Bernstein, Talat Bessissow, Brian Bressler, Frank Hoentjen, (unknown), Yvette Leung, Christopher Ma, John K. Marshall, Neeraj Narula, (unknown), Jeffrey D. McCurdy, Sanjay K. Murthy, (unknown), Greg Rosenfeld, Raquel Milgrom, Mark S. Silverberg, Vipul Jairath	1
5	OP15 High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trial 2024 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Nathan den Broeder, Debora de Jong, (unknown), Marjolijn Duijvestein, Herma H. Fidder, (unknown), Meike M. Hirdes, Andrea E. van der Meulen‐de Jong, (unknown), Philip W. Voorneveld, Nanne K.H. de Boer, Charlotte P. Peters, Bas Oldenburg, Frank Hoentjen	4
6	Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal 2023 ·PharmacoEconomics ·Antoinette D. I. van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, (unknown), Lisa Stirk, (unknown), Tim M. Govers, Frank Hoentjen, Manuela Joore, Sabine Grimm	2
7	Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship 2023 ·United European Gastroenterology Journal ·(unknown), Sjoerd G. Elias, Evelien Dekker, Herma H. Fidder, Frank Hoentjen, Joren R. ten Hove, Jeroen Maljaars, Andrea E. van der Meulen‐de Jong, Erik Mooiweer, (unknown), (unknown), Cyriel Y. Ponsioen, Fiona D M van Schaik, Bas Oldenburg, (unknown)	3
8	Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease 2023 ·Digestive Diseases and Sciences ·(unknown), Vince Biemans, Dirk Jan A. R. Moes, Frank Hoentjen, Rob ter Heine, Jeroen Maljaars, Rosaline Theeuwen, Marieke Pierik, Marjolijn Duijvestein, Andrea E. van der Meulen‐de Jong, (unknown)	10
9	Bacterial Oncotraits Rather than Spatial Organization Are Associated with Dysplasia in Ulcerative Colitis 2023 ·Journal of Crohn s and Colitis ·Carlijn E. Bruggeling, (unknown), Daniel Garza, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Irıs D. Nagtegaal, Bas E. Dutilh, Frank Hoentjen, Annemarie Boleij	5
10	Preoperative screening and prehabilitation strategies prior to ileocolic resection in patients with Crohn’s disease are not incorporated in routine care 2023 ·International Journal of Colorectal Disease ·(unknown), Oddeke van Ruler, Laurents Stassen, (unknown), (unknown), Gerard Dijkstra, Marjo Campmans‐Kuijpers, N.L.U. van Meeteren, Bart C. Bongers, Mariëlle Romberg‐Camps, Sander van der Marel, Frank Hoentjen, K. W. van Dongen, Rachel West, J van der Woude, Annemarie C. de Vries, (unknown)	2
11	P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis 2022 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Lauranne Derikx, Nathan den Broeder, Tessa E H Römkens, Frank Hoentjen	2
12	POS0669 HYPOGLYCAEMIA FOLLOWING JAK INHIBITOR TREATMENT IN DIABETES MELLITUS PATIENTS WITH RHEUMATOID ARTHRITIS 2021 ·Annals of the Rheumatic Diseases ·(unknown), Florence van Hunsel, Sander W. Tas, Michael T. Nurmohamed, (unknown), (unknown), Frank Hoentjen, Martijn B. A. van Doorn, (unknown), Eugène van Puijenbroek, Naomi T. Jessurun	1
13	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals 2021 ·The Journal of Rheumatology ·(unknown), Naomi T. Jessurun, Sander W. Tas, Bart J. F. van den Bemt, Michael T. Nurmohamed, Martijn B. A. van Doorn, Phyllis I. Spuls, Astrid van Tubergen, Peter M. ten Klooster, Eugène van Puijenbroek, Frank Hoentjen, Harald E. Vonkeman	0
14	Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study 2021 ·Journal of Crohn s and Colitis ·(unknown), Vince Biemans, Frank Hoentjen, Nanne K.H. de Boer, Alexander Bodelier, Gerard Dijkstra, Willemijn A. van Dop, J Haans, Jeroen M. Jansen, Jeroen Maljaars, Sander van der Marel, Bas Oldenburg, Cyriel Y. Ponsioen, Marijn C. Visschedijk, Annemarie C. de Vries, Rachel West, C. Janneke van der Woude, Marieke Pierik, Marjolijn Duijvestein, Andrea E. van der Meulen‐de Jong	26
15	Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study 2020 ·BMJ Open ·Lisa Smits, (unknown), Wietske Kievit, Dirk J. de Jong, Annemarie C. de Vries, Frank Hoentjen, C. Janneke van der Woude, (unknown)	2
16	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment 2020 ·Alimentary Pharmacology & Therapeutics ·Vince Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, Mark Löwenberg, Nanne K.H. de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M. Jansen, Alexander Bodelier, Rachel West, Annemarie C. de Vries, J Haans, Dirk de Jong, Frank Hoentjen, Marieke Pierik, (unknown)	76
17	Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study 2020 ·Alimentary Pharmacology & Therapeutics ·(unknown), Vince Biemans, Marieke Pierik, Gerard Dijkstra, Mark Löwenberg, Sander van der Marel, Nanne K.H. de Boer, Alexander Bodelier, Jeroen M. Jansen, Rachel West, J Haans, Willemijn A. van Dop, Rinse K. Weersma, Frank Hoentjen, Jeroen Maljaars, (unknown)	29
18	Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis 2019 ·Alimentary Pharmacology & Therapeutics ·Melek Simsek, Birgit I. Lissenberg‐Witte, (unknown), (unknown), Frank Hoentjen, Bas Oldenburg, Cyriel Y. Ponsioen, C. Janneke van der Woude, Andrea E. van der Meulen‐de Jong, Marieke Pierik, Gerard Dijkstra, Nanne K.H. de Boer	3
19	Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma 2017 ·Inflammatory Bowel Diseases ·Loes H.C. Nissen, Marieke Pierik, Lauranne Derikx, E.M.G.J. de Jong, Wietske Kievit, Tim van den Heuvel, Alexander R. van Rosendael, Elsemieke I. Plasmeijer, Pieter Dewint, Rob H.A. Verhoeven, Lucy Overbeek, Irıs D. Nagtegaal, Frank Hoentjen, Andrea E. van der Meulen‐de Jong	15
20	Better survival of renal cell carcinoma in patients with inflammatory bowel disease 2015 ·Oncotarget ·Lauranne Derikx, (unknown), Loes H.C. Nissen, Joost P.H. Drenth, Carla M. van Herpen, Wietske Kievit, Rob H.A. Verhoeven, Peter F.A. Mulders, Christina A. Hulsbergen‐van de Kaa, Marye J. Boers‐Sonderen, Tim van den Heuvel, Marieke Pierik, Irıs D. Nagtegaal, Frank Hoentjen	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact